Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. uri icon

authors

  • Salhotra, Amandeep
  • Koller, Paul
  • Andrew Artz, MD, MS
  • Forman, Stephen
  • Nakamura, Ryotaro
  • Stein, Anthony
  • Marcucci, Guido
  • Aldoss, Ibrahim
  • Pullarkat, Vinod
  • Tsai, Ni-Chun
  • Zhang, Jianying
  • Ngo, Dat
  • Aribi, Ahmed
  • Sandhu, Karamjeet
  • Ball, Brian
  • Al-Malki, Monzr
  • Ali, Haris

publication date

  • January 1, 2021